Sagimet Biosciences Files 8-K
Ticker: SGMT · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1400118
Sentiment: neutral
Topics: financial-statements, exhibits, company-update
TL;DR
Sagimet Biosciences filed an 8-K on 10/23/25 for financial statements & exhibits.
AI Summary
Sagimet Biosciences Inc. filed an 8-K on October 23, 2025, reporting on financial statements and exhibits. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and headquartered in San Mateo, California.
Why It Matters
This filing provides an update on Sagimet Biosciences' financial reporting and exhibits, which is crucial for investors to assess the company's current financial status and any material events.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- 3-V Biosciences, Inc. (company) — Former Company Name
- October 23, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Mateo, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of October 23, 2025.
When was Sagimet Biosciences Inc. incorporated?
Sagimet Biosciences Inc. was incorporated in Delaware.
What was Sagimet Biosciences Inc.'s former name?
Sagimet Biosciences Inc.'s former name was 3-V Biosciences, Inc.
Where are Sagimet Biosciences Inc.'s principal executive offices located?
Sagimet Biosciences Inc.'s principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the Commission File Number for Sagimet Biosciences Inc.?
The Commission File Number for Sagimet Biosciences Inc. is 001-41742.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-23 16:06:02
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2529317d1_8k.htm (8-K) — 27KB
- tm2529317d1_ex99-1.htm (EX-99.1) — 86KB
- tm2529317d1_ex99-1img001.jpg (GRAPHIC) — 143KB
- tm2529317d1_ex99-1img002.jpg (GRAPHIC) — 325KB
- tm2529317d1_ex99-1img003.jpg (GRAPHIC) — 163KB
- tm2529317d1_ex99-1img004.jpg (GRAPHIC) — 130KB
- tm2529317d1_ex99-1img005.jpg (GRAPHIC) — 125KB
- tm2529317d1_ex99-1img006.jpg (GRAPHIC) — 117KB
- tm2529317d1_ex99-1img007.jpg (GRAPHIC) — 104KB
- tm2529317d1_ex99-1img008.jpg (GRAPHIC) — 125KB
- tm2529317d1_ex99-1img009.jpg (GRAPHIC) — 110KB
- tm2529317d1_ex99-1img010.jpg (GRAPHIC) — 123KB
- tm2529317d1_ex99-1img011.jpg (GRAPHIC) — 93KB
- tm2529317d1_ex99-1img012.jpg (GRAPHIC) — 134KB
- tm2529317d1_ex99-1img013.jpg (GRAPHIC) — 142KB
- tm2529317d1_ex99-1img014.jpg (GRAPHIC) — 103KB
- tm2529317d1_ex99-1img015.jpg (GRAPHIC) — 93KB
- tm2529317d1_ex99-1img016.jpg (GRAPHIC) — 136KB
- tm2529317d1_ex99-1img017.jpg (GRAPHIC) — 90KB
- tm2529317d1_ex99-1img018.jpg (GRAPHIC) — 161KB
- tm2529317d1_ex99-1img019.jpg (GRAPHIC) — 164KB
- tm2529317d1_ex99-1img020.jpg (GRAPHIC) — 169KB
- tm2529317d1_ex99-1img021.jpg (GRAPHIC) — 122KB
- tm2529317d1_ex99-1img022.jpg (GRAPHIC) — 163KB
- tm2529317d1_ex99-1img023.jpg (GRAPHIC) — 103KB
- tm2529317d1_ex99-1img024.jpg (GRAPHIC) — 98KB
- tm2529317d1_ex99-1img025.jpg (GRAPHIC) — 120KB
- tm2529317d1_ex99-1img026.jpg (GRAPHIC) — 109KB
- tm2529317d1_ex99-1img027.jpg (GRAPHIC) — 162KB
- tm2529317d1_ex99-1img028.jpg (GRAPHIC) — 84KB
- tm2529317d1_ex99-1img029.jpg (GRAPHIC) — 138KB
- tm2529317d1_ex99-1img030.jpg (GRAPHIC) — 116KB
- tm2529317d1_ex99-1img031.jpg (GRAPHIC) — 197KB
- tm2529317d1_ex99-1img032.jpg (GRAPHIC) — 170KB
- tm2529317d1_ex99-1img033.jpg (GRAPHIC) — 120KB
- tm2529317d1_ex99-1img034.jpg (GRAPHIC) — 162KB
- tm2529317d1_ex99-1img035.jpg (GRAPHIC) — 89KB
- tm2529317d1_ex99-1img036.jpg (GRAPHIC) — 68KB
- tm2529317d1_ex99-1img037.jpg (GRAPHIC) — 135KB
- tm2529317d1_ex99-1img038.jpg (GRAPHIC) — 147KB
- tm2529317d1_ex99-1img039.jpg (GRAPHIC) — 142KB
- tm2529317d1_ex99-1img040.jpg (GRAPHIC) — 152KB
- tm2529317d1_ex99-1img041.jpg (GRAPHIC) — 131KB
- tm2529317d1_ex99-1img042.jpg (GRAPHIC) — 176KB
- tm2529317d1_ex99-1img043.jpg (GRAPHIC) — 122KB
- tm2529317d1_ex99-1img044.jpg (GRAPHIC) — 150KB
- tm2529317d1_ex99-1img045.jpg (GRAPHIC) — 142KB
- tm2529317d1_ex99-1img046.jpg (GRAPHIC) — 142KB
- tm2529317d1_ex99-1img047.jpg (GRAPHIC) — 91KB
- tm2529317d1_ex99-1img048.jpg (GRAPHIC) — 71KB
- tm2529317d1_ex99-1img049.jpg (GRAPHIC) — 160KB
- tm2529317d1_ex99-1img050.jpg (GRAPHIC) — 144KB
- tm2529317d1_ex99-1img051.jpg (GRAPHIC) — 129KB
- 0001104659-25-101819.txt ( ) — 9567KB
- sgmt-20251023.xsd (EX-101.SCH) — 3KB
- sgmt-20251023_lab.xml (EX-101.LAB) — 33KB
- sgmt-20251023_pre.xml (EX-101.PRE) — 22KB
- tm2529317d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated October 23, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: October 23, 2025 By: /s/ David Happel David Happel Chief Executive Officer